MAP2K7 and melanoma: While melanoma cell response to targeted therapeutics and their withdrawal after short exposure to drugs is a frequent subject of investigation (for example, [14,37]), reports on alterations induced by drug holiday and drug rechallenge in preclinical models of stable melanoma resistant to BRAFV600/MEK inhibitors [18,19,20,21,22,23,24,25] or in melanoma patients who developed resistance [38,39,40,41,42,43,44] are limited.